Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Breast Cancer Res Treat. 2022 May 31;194(2):231–241. doi: 10.1007/s10549-022-06633-0

Fig. 4. Association of the ROS score with the intratumor heterogeneity, homologous recombination deficiency (HRD), and mutation-related score in the TCGA cohort.

Fig. 4

Boxplots of homologous recombination defects (HRD), and intratumor heterogeneity, and the mutation-related scores; silent and non-silent mutation rate, fraction altered, single nucleotide variation (SNV) neoantigens, by low and high ROS score groups. The median value was used as a cut-off to divide two score groups. P-values were calculated by the Mann-Whitney U test